Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.909 USD | +10.18% | +45.53% | -35.07% |
04-26 | Foreign automakers eager for Chinese partners at Beijing auto show | RE |
04-25 | Battle for 'tech luxury' in China as EVs get smarter - and cheaper | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.07% | 125M | C+ | ||
-2.63% | 103B | B+ | ||
+1.62% | 95.28B | B+ | ||
+1.46% | 22.15B | B | ||
-16.67% | 21.02B | B+ | ||
-8.58% | 18.15B | A- | ||
-38.74% | 16.73B | A- | ||
-13.21% | 16.05B | B | ||
+5.41% | 13.68B | C+ | ||
+33.57% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCRB Stock
- Ratings Seres Therapeutics, Inc.